What the FDA labels say about taking them together
Atazanavir and lomitapide
Atazanavir's FDA label of August 6, 2025 names lomitapide in its contraindications section; the lomitapide label PlainMeds reads does not name atazanavir. The atazanavir label: “Coadministration of REYATAZ with lomitapide is contraindicated. This is due to the potential for risk of markedly increased transaminase levels and hepatotoxicity associated with increased plasma concentrations of …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.).
What does the atazanavir label say about lomitapide?
Atazanavir label, contraindicationsDrug Class: Lipid-Modifying Agents:; Drugs within class that are contraindicated with atazanavir capsules: Lomitapide, lovastatin, simvastatin
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Other Lipid Modifying Agents: lomitapide; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ lomitapide; Clinical Comment: Coadministration of atazanavir with lomitapide is contraindicated. This is due to the potential for risk of markedly increased transaminase levels and hepatotoxicity associated with increased plasma concentrations of lomitapide. The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir [see ].
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the lomitapide label say about atazanavir?
Lomitapide's label (effective March 30, 2026) does not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Lomitapide | |
|---|---|---|
| Labeled for | HIV | High cholesterol |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once